泛免疫炎症值在消化系统肿瘤预后评估中的 研究进展
Research Progress of Pan-Immune-Inflammation Value in Prognostic Assessment of Digestive System Tumors
DOI: 10.12677/acm.2026.1672635, PDF,   
作者: 杨体上, 周 嘉：右江民族医学院研究生学院，广西 百色；黄许森*：右江民族医学院附属医院胃肠外科，广西 百色
关键词: 泛免疫炎症值；消化系统肿瘤；预后；生物标志物；炎症；Pan-Immune-Inflammation Value； Digestive System Tumors； Prognosis； Biomarker； Inflammation
摘要: 肿瘤相关炎症反应以及宿主免疫状态在肿瘤的发生与发展进程中发挥着关键作用。泛免疫炎症值(Pan-Immune-Inflammation Value, PIV)作为一种新型综合性炎症标志物，是基于外周血中性粒细胞、血小板、单核细胞以及淋巴细胞计数计算而得。与传统炎症指标相比，PIV更为全面地体现了肿瘤微环境中促肿瘤炎症反应与抗肿瘤免疫应答之间的相互作用。近年来，众多研究显示，PIV在多种消化系统肿瘤(涵盖食管癌、胃癌、结直肠癌、肝癌以及胰腺癌)的预后预测方面呈现出稳定且卓越的价值。本文系统综述PIV在不同消化系统肿瘤中的预后作用，旨在为消化系统肿瘤的精准预后分层与治疗决策提供一个新的参考依据。
Abstract: Tumor-associated inflammatory responses and the host immune status play critical roles in the occurrence and progression of tumors. The Pan-Immune-Inflammation Value (PIV), as a novel comprehensive inflammatory biomarker, is calculated based on peripheral blood neutrophil, platelet, monocyte, and lymphocyte counts. Compared with traditional inflammatory indicators, PIV more comprehensively reflects the interplay between pro-tumor inflammatory responses and anti-tumor immune responses within the tumor microenvironment. In recent years, numerous studies have demonstrated that PIV exhibits stable and excellent prognostic value in various digestive system tumors, including esophageal cancer, gastric cancer, colorectal cancer, liver cancer, and pancreatic cancer. This article systematically reviews the prognostic role of PIV in different digestive system tumors, aiming to provide a new reference for precise prognostic stratification and treatment decision-making in digestive system tumors.
文章引用：杨体上, 黄许森, 周嘉. 泛免疫炎症值在消化系统肿瘤预后评估中的 研究进展[J]. 临床医学进展, 2026, 16(7): 1206-1214. https://doi.org/10.12677/acm.2026.1672635

参考文献

[1] Cao, W., Qin, K., Li, F. and Chen, W. (2024) Comparative Study of Cancer Profiles between 2020 and 2022 Using Global Cancer Statistics (GLOBOCAN). Journal of the National Cancer Center, 4, 128-134. [Google Scholar] [CrossRef] [PubMed]
[2] Bray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R.L., Soerjomataram, I., et al. (2024) Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 74, 229-263. [Google Scholar] [CrossRef] [PubMed]
[3] Siegel, R.L., Giaquinto, A.N. and Jemal, A. (2024) Cancer Statistics, 2024. CA: A Cancer Journal for Clinicians, 74, 12-49. [Google Scholar] [CrossRef] [PubMed]
[4] Wen, Y., Zhu, Y., Zhang, C., Yang, X., Gao, Y., Li, M., et al. (2022) Chronic Inflammation, Cancer Development and Immunotherapy. Frontiers in Pharmacology, 13, Article 1040163. [Google Scholar] [CrossRef] [PubMed]
[5] Li, Z., Li, J., Bai, X., Huang, X. and Wang, Q. (2025) Tumor Microenvironment as a Complex Milieu Driving Cancer Progression: A Mini Review. Clinical and Translational Oncology, 27, 1943-1952. [Google Scholar] [CrossRef] [PubMed]
[6] Fucà, G., Guarini, V., Antoniotti, C., Morano, F., Moretto, R., Corallo, S., et al. (2020) The Pan-Immune-Inflammation Value Is a New Prognostic Biomarker in Metastatic Colorectal Cancer: Results from a Pooled-Analysis of the Valentino and TRIBE First-Line Trials. British Journal of Cancer, 123, 403-409. [Google Scholar] [CrossRef] [PubMed]
[7] Guven, D.C., Sahin, T.K., Erul, E., Kilickap, S., Gambichler, T. and Aksoy, S. (2022) The Association between the Pan-Immune-Inflammation Value and Cancer Prognosis: A Systematic Review and Meta-analysis. Cancers, 14, Article 2675. [Google Scholar] [CrossRef] [PubMed]
[8] Yu, H.J., Ren, S. and Xia, J.Q. (2023) Prognostic Significance of the Pretreatment Pan-Immune-Inflammation Value in Cancer Patients: An Updated Meta-Analysis of 30 Studies. Frontiers in Nutrition, 10, Article 1259929. [Google Scholar] [CrossRef] [PubMed]
[9] Dai, J., Sun, X., Lin, B., Sun, Y. and Chen, L. (2026) Pan-Immune-Inflammation Value Is Associated with All-Cause and Cause-Specific Mortality among Individuals with Cancer Survivors: A Population-Based Longitudinal Cohort Study. Cancer Treatment and Research Communications, 46, Article ID: 101070. [Google Scholar] [CrossRef] 
[10] Yu, D., Liu, J., Meng, C., Liu, B. and Liao, J. (2024) Pan-Immune-Inflammation Value as a Novel Prognostic Biomarker for Digestive System Cancers: A Meta-analysis. World Journal of Surgical Oncology, 22, 306-312. [Google Scholar] [CrossRef] [PubMed]
[11] Mukaida, N., Sasaki, S. and Baba, T. (2020) Two-Faced Roles of Tumor-Associated Neutrophils in Cancer Development and Progression. International Journal of Molecular Sciences, 21, Article 3457. [Google Scholar] [CrossRef] [PubMed]
[12] Liao, K., Zhang, X., Liu, J., Teng, F., He, Y., Cheng, J., et al. (2023) The Role of Platelets in the Regulation of Tumor Growth and Metastasis: The Mechanisms and Targeted Therapy. MedComm, 4, e350. [Google Scholar] [CrossRef] [PubMed]
[13] Tan, Y., Wang, M., Zhang, Y., Ge, S., Zhong, F., Xia, G., et al. (2021) Tumor-Associated Macrophages: A Potential Target for Cancer Therapy. Frontiers in Oncology, 11, Article 693517. [Google Scholar] [CrossRef] [PubMed]
[14] Hosseinalizadeh, H., Rabiee, F., Eghbalifard, N., Rajabi, H., Klionsky, D.J. and Rezaee, A. (2023) Regulating the Regulatory T Cells as Cell Therapies in Autoimmunity and Cancer. Frontiers in Medicine, 10, Article 1244298. [Google Scholar] [CrossRef] [PubMed]
[15] Zhu, H., Ma, X., Ye, T., Wang, H., Wang, Z., Liu, Q., et al. (2023) Esophageal Cancer in China: Practice and Research in the New Era. International Journal of Cancer, 152, 1741-1751. [Google Scholar] [CrossRef] [PubMed]
[16] Feng, J., Wang, L., Yang, X., Chen, Q. and Cheng, X. (2023) Clinical Utility of Preoperative Pan-Immune-Inflammation Value (PIV) for Prognostication in Patients with Esophageal Squamous Cell Carcinoma. International Immunopharmacology, 123, Article ID: 110805. [Google Scholar] [CrossRef] [PubMed]
[17] Baba, Y., Nakagawa, S., Toihata, T., Harada, K., Iwatsuki, M., Hayashi, H., et al. (2022) Pan-Immune-Inflammation Value and Prognosis in Patients with Esophageal Cancer. Annals of Surgery Open, 3, e113. [Google Scholar] [CrossRef] [PubMed]
[18] Feng, J., Wang, L., Yang, X., Chen, Q. and Cheng, X. (2024) Pretreatment Pan-Immune-Inflammation Value (PIV) in Predicting Therapeutic Response and Clinical Outcomes of Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell Carcinoma. Annals of Surgical Oncology, 31, 272-283. [Google Scholar] [CrossRef] [PubMed]
[19] Thuss-Patience, P. and Stein, A. (2022) Immunotherapy in Squamous Cell Cancer of the Esophagus. Current Oncology, 29, 2461-2471. [Google Scholar] [CrossRef] [PubMed]
[20] Cheng, X., Luo, K., Gao, Y., Wang, R., Liu, S., Li, Q., et al. (2025) Pan-immune-inflammation Value Predicts Survival of Patients with Oesophageal Squamous Cell Carcinoma Receiving Immunotherapy and Chemoradiotherapy: A Pooled Analysis of Two Phase II Trials. Annals of Medicine, 57, Article ID: 2576639. [Google Scholar] [CrossRef] 
[21] 闫超, 陕飞, 李子禹. 2020年全球胃癌负担分析:聚焦中国流行现状[J]. 中国肿瘤, 2023, 32(3): 161-170.
[22] Wang, M., Wang, J., Wang, X., Li, J., Hu, Y., Ji, H., et al. (2026) Pan-Immune-Inflammation Value Is a Novel Prognostic Biomarker in PT2-4 Gastric Cancer. Frontiers in Medicine, 13, Article 1802591. [Google Scholar] [CrossRef] 
[23] Senocak, D., Karakullukcu, M., Ozkan, E., Bilgi, O. and Ozgun, M.A. (2026) Prognostic Significance of the Pan-Immune-Inflammatory Value (PIV) in Gastric Cancer: A Retrospective Cohort Study. BMC Cancer, 26, Article No. 400. [Google Scholar] [CrossRef] 
[24] Zhong, W., Ding, S., Li, R., Liu, C., Huang, H. and Yu, J. (2026) Clinical Value of Geriatric Nutritional Risk Index and Pan-Immune-Inflammation Value in Locally Advanced Gastric Cancer Receiving Neoadjuvant Chemotherapy. World Journal of Gastrointestinal Oncology, 18, Article ID: 115387. [Google Scholar] [CrossRef] 
[25] Gulmez, A., Coskun, H., Koseci, T., Ata, S., Bozkurt, B. and Cil, T. (2023) Effect of Microsatellite Status and Pan-Immune-Inflammation Score on Pathological Response in Patients with Clinical Stage III Stomach Cancer Treated with Perioperative Chemotherapy. Medicina, 59, Article 1625. [Google Scholar] [CrossRef] [PubMed]
[26] 汪婷婷, 曾会会, 胡婷, 等. 泛免疫炎症值对HER-2阴性晚期胃癌免疫联合化疗原发性耐药的预测[J]. 锦州医科大学学报, 2024, 45(6): 31-36.
[27] Wu, S., Zhang, Y., Lin, Z. and Wei, M. (2025) Global Burden of Colorectal Cancer in 2022 and Projections to 2050: Incidence and Mortality Estimates from Globocan. BMC Cancer, 25, Article No. 1770. [Google Scholar] [CrossRef] 
[28] Yang, X., Liu, H., Liu, D., Tong, C., Liang, X. and Chen, R. (2022) Prognostic Value of Pan-Immune-Inflammation Value in Colorectal Cancer Patients: A Systematic Review and Meta-Analysis. Frontiers in Oncology, 12, Article 1036890. [Google Scholar] [CrossRef] [PubMed]
[29] Li, K., Chen, Y., Zhang, Z., Wang, K., Sulayman, S., Zeng, X., et al. (2025) Preoperative Pan-Immuno-Inflammatory Values and Albumin-To-Globulin Ratio Predict the Prognosis of Stage I-III Colorectal Cancer. Scientific Reports, 15, Article No. 11517. [Google Scholar] [CrossRef] [PubMed]
[30] Zhao, H., Chen, X., Zhang, W., Cheng, D., Lu, Y., Wang, C., et al. (2022) Pan-Immune-Inflammation Value Is Associated with the Clinical Stage of Colorectal Cancer. Frontiers in Surgery, 9, Article 996844. [Google Scholar] [CrossRef] [PubMed]
[31] Sato, S., Shimizu, T., Ishizuka, M., Suda, K., Shibuya, N., Hachiya, H., et al. (2022) The Preoperative Pan-Immune-Inflammation Value Is a Novel Prognostic Predictor for with Stage I-III Colorectal Cancer Patients Undergoing Surgery. Surgery Today, 52, 1160-1169. [Google Scholar] [CrossRef] [PubMed]
[32] Seo, Y.J., Kim, K.E., Jeong, W.K., Baek, S.K. and Bae, S.U. (2024) Effect of Preoperative Pan-Immune-Inflammation Value on Clinical and Oncologic Outcomes after Colorectal Cancer Surgery: A Retrospective Study. Annals of Surgical Treatment and Research, 106, 169-177. [Google Scholar] [CrossRef] [PubMed]
[33] Corti, F., Lonardi, S., Intini, R., Salati, M., Fenocchio, E., Belli, C., et al. (2021) The Pan-Immune-Inflammation Value in Microsatellite Instability-High Metastatic Colorectal Cancer Patients Treated with Immune Checkpoint Inhibitors. European Journal of Cancer, 150, 155-167. [Google Scholar] [CrossRef] [PubMed]
[34] Wang, Q., Zhong, W., Xiao, Y., Lin, G., Lu, J., Xu, L., et al. (2025) Pan‐Immune‐Inflammation Value Predicts Immunotherapy Response and Reflects Local Antitumor Immune Response in Rectal Cancer. Cancer Science, 116, 350-366. [Google Scholar] [CrossRef] [PubMed]
[35] Pérez-Martelo, M., González-García, A., Vidal-Ínsua, Y., Blanco-Freire, C., Brozos-Vázquez, E.M., Abdulkader-Nallib, I., et al. (2022) Clinical Significance of Baseline Pan-Immune-Inflammation Value and Its Dynamics in Metastatic Colorectal Cancer Patients under First-Line Chemotherapy. Scientific Reports, 12, Article No. 6893. [Google Scholar] [CrossRef] [PubMed]
[36] Zheng, S., Chan, S.W., Liu, F., Liu, J., Chow, P.K.H., Toh, H.C., et al. (2024) Hepatocellular Carcinoma: Current Drug Therapeutic Status, Advances and Challenges. Cancers, 16, Article 1582. [Google Scholar] [CrossRef] [PubMed]
[37] Fu, H., Wang, Y. and Xiang, B. (2025) Pan-Immune-Inflammation Value as a Prognostic Biomarker for Hepatocellular Carcinoma Patients Undergoing Hepatectomy. Journal of Inflammation Research, 18, 6411-6425. [Google Scholar] [CrossRef] [PubMed]
[38] Liang, X., Bu, J., Jiang, Y., Zhu, S., Ye, Q., Deng, Y., et al. (2024) Prognostic Significance of Pan-Immune-Inflammation Value in Hepatocellular Carcinoma Treated by Curative Radiofrequency Ablation: Potential Role for Individualized Adjuvant Systemic Treatment. International Journal of Hyperthermia, 41, Article ID: 2355279. [Google Scholar] [CrossRef] [PubMed]
[39] Karadag, I., Karakaya, S., Yilmaz, M.E., et al. (2022) The Potential Prognostic Novel Markers PIV and PILE Score to Predict Survival Outcomes at Hepatocellular Cancer. European Review for Medical and Pharmacological Sciences, 26, 7679-7686.
[40] Wei, Y., Mao, D., Liu, T., Wu, W., Yang, Z. and Liu, X. (2025) The Predictive Value of PIV, PLR, LMR, NPR, and NLR for the Prognosis of Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma Combined with Liver Cirrhosis. BMC Gastroenterology, 25, Article No. 315. [Google Scholar] [CrossRef] [PubMed]
[41] Cai, J., Chen, H., Lu, M., Zhang, Y., Lu, B., You, L., et al. (2021) Advances in the Epidemiology of Pancreatic Cancer: Trends, Risk Factors, Screening, and Prognosis. Cancer Letters, 520, 1-11. [Google Scholar] [CrossRef] [PubMed]
[42] Aydin, A.A., Kayikcioglu, E., Unlu, A., Acun, M., Guzel, H.G., Yavuz, R., et al. (2024) Pan-Immune-Inflammation Value as a Novel Prognostic Biomarker for Advanced Pancreatic Cancer. Cureus, 16, e71251. [Google Scholar] [CrossRef] [PubMed]
[43] Topkan, E., Selek, U., Kucuk, A. and Pehlivan, B. (2022) Low Pre-Chemoradiotherapypan-Immune-Inflammation Value (PIV) Measures Predict Better Survival Outcomes in Locally Advanced Pancreatic Adenocarcinomas. Journal of Inflammation Research, 15, 5413-5423. [Google Scholar] [CrossRef] [PubMed]

为你推荐